ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc (ALDX)

5.37
0.05
(0.94%)
At close: 12 October 7:00AM
5.37
0.00
( 0.00% )
After Hours: 7:30AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.37
Bid
4.91
Offer
5.45
Volume
410,396
5.26 Day's Range 5.41
1.42 52 Week Range 6.5476
Market Cap
Previous Close
5.32
Open
5.32
Last Trade
2
@
5.37
Last Trade Time
Financial Volume
US$ 2,189,968
VWAP
5.3362
Average Volume (3m)
525,505
Shares Outstanding
59,421,551
Dividend Yield
-
PE Ratio
-8.52
Earnings Per Share (EPS)
-0.63
Revenue
-
Net Profit
-37.54M

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye dis... Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Aldeyra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALDX. The last closing price for Aldeyra Therapeutics was US$5.32. Over the last year, Aldeyra Therapeutics shares have traded in a share price range of US$ 1.42 to US$ 6.5476.

Aldeyra Therapeutics currently has 59,421,551 shares in issue. The market capitalisation of Aldeyra Therapeutics is US$316.12 million. Aldeyra Therapeutics has a price to earnings ratio (PE ratio) of -8.52.

ALDX Latest News

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0751.41643059495.2955.485.033449655.28217673CS
4-0.885-14.14868105526.2556.35.034561045.53798929CS
121.538.75968992253.876.54763.145255055.0695457CS
261.0724.88372093024.36.54763.14406104.51380848CS
52-0.58-9.747899159665.956.54761.4211245333.0597732CS
156-3.04-36.14744351968.4111.971.429198354.97274535CS
2600.040.7504690431525.3315.951.429090256.80538229CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.13M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.47M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
11.04M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
3.19M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
993.24k
VEEAVeea Inc
US$ 3.27
(-23.24%)
284.79k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
257.56k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
339.71M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
270.64M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
170.15M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
165.58M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.13M

ALDX Discussion

View Posts
jgrabar jgrabar 2 weeks ago
Current Aldeyra shareholders who have continuously held Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/ to learn more. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.
πŸ‘οΈ0
TechandBio TechandBio 3 weeks ago
Another big winner for me this year ICCM is next!

$ALDX
πŸ‘οΈ0
Investor2014 Investor2014 2 months ago
Sold half at around $5’ish for about 50% profit looking to buy back lower awaiting NDA filing and like decision dates for Reproxalap.
πŸ‘οΈ0
peterus peterus 2 months ago
what your thoughts here for the future?
πŸ‘οΈ0
peterus peterus 2 months ago
hi bro you know a good discord or web for parma and bioΒ΄s
πŸ‘οΈ0
peterus peterus 2 months ago
when offering lol
πŸ‘οΈ0
Investor2014 Investor2014 2 months ago
No one happy here?
πŸ‘οΈ0
Investor2014 Investor2014 2 months ago
Will the dry eye confirmatory P3 trial prove successful this morning? Hard to call, but leaning towards yes.
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
ALDX under $4
πŸ‘οΈ0
jgrabar jgrabar 6 months ago
NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (β€œNDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 7 months ago
Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 11 months ago
I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)
πŸ‘οΈ0
green maschine green maschine 11 months ago
Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

πŸ‘οΈ0
green maschine green maschine 11 months ago
Yep. I snatched up some of this pre-market.
πŸ‘οΈ0
Invest-in-America Invest-in-America 11 months ago
ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!
πŸ‘οΈ0
Investor2014 Investor2014 12 months ago
I bought to average down today, it seems a sensible move.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 12 months ago
With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.
πŸ‘οΈ0
Investor2014 Investor2014 12 months ago
Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 12 months ago
Ouch
πŸ‘οΈ0
Investor2014 Investor2014 1 year ago
A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…
πŸ‘οΈ0
InvestorPhilia4 InvestorPhilia4 2 years ago
I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Yet another great day for aldeyra.

No one invested here?
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Another great day for Aldeyra. In due course probably pay handsomely.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Good day for Aldeyra!
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
That’s biotech.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
what I meant was the time line

mid 2022

πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Agree and believe that is what I just said.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
yeah but heres the kicker

ALDX
Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

Could be fine not least given that secondary p-value.

Still hope!
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Yeah not good.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
T1
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
ADX-1612 and ADX-1615, Chaperome Inhibitors

Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
I agree, ALDX has great potential.
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!
πŸ‘οΈ0
Rayn_Makr Rayn_Makr 3 years ago
Perceptive Advisors SEC form 4
3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.
πŸ‘οΈ0
make it happen make it happen 3 years ago
I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Bought in again @$12.89.
πŸ‘οΈ0
make it happen make it happen 3 years ago
Huge $125,000,000 offering & can add another $18,750,000 million
πŸ‘οΈ0
make it happen make it happen 3 years ago
Most def
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

Plenty time to buy back in cheaper, which should be a nice long term hold.
πŸ‘οΈ0
ClayTrader ClayTrader 3 years ago
* * $ALDX Video Chart 04-27-2021 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
make it happen make it happen 3 years ago
Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever
πŸ‘οΈ0
altruism altruism 3 years ago
Billion dollars traded today so far
πŸ‘οΈ0
make it happen make it happen 3 years ago
Yes, usually have something going on or at least some kind revenues from something. Not just spending money.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock